"/> Tocris Bioscience™ MRTX 849 | B-LABO France

Tocris Bioscience™ MRTX 849

Réf. : BL-RE-124972Réf. fabricant : 18728066 50 mg
1 237,55 € HT

Mutation-selective inhibitor of KRASG12C

Nom chimique ou matériau
4-[7-(8-Chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-[[(2 S)-1-methyl-2-pyrrolidinyl]methoxy]pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoro-1-oxo-2-propen-1-yl)-(2 S)-2-piperazineacetonitrile
CAS
2326521-71-3
Quantité
50 mg
Cible
Ras GTPase Inhibitors
Formule moléculaire
C32H35ClFN7O2
Marque
Tocris Bioscience

MRTX 849 is a mutant-selective inhibitor of KRASG12C (IC50 = 142 nM). MRTX 849 covalently binds to KRASG12C at the cysteine at residue 12 and inhibits KRAS-dependent signal transduction by locking the protein in its inactive GDP-bound state. MRTX 849 induces pronounced tumor regression in 17 of 26 (65%) KRASG12C -positive cell lines and patient-derived xenograft models from multiple tumor types. It is orally bioavailable.

Caractéristiques techniques

MarqueTocris Bioscience
Réf. B-LABOBL-RE-124972
Réf. fabricant18728066
Nom chimique ou matériau4-[7-(8-Chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-[[(2 S)-1-methyl-2-pyrrolidinyl]methoxy]pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoro-1-oxo-2-propen-1-yl)-(2 S)-2-piperazineacetonitrile
CAS2326521-71-3
Quantité50 mg
CibleRas GTPase Inhibitors
Formule moléculaireC<sub>32</sub>H<sub>35</sub>ClFN<sub>7</sub>O<sub>2</sub>
Pureté98%
Une question, une configuration particulière ?
Contactez-nous pour un devis.